“Growing Use of Prokinetic Agents in Chronic Idiopathic Constipation Treatment”
A key trend driving growth in the chronic idiopathic constipation (CIC) treatment market is the increasing use of prokinetic agents. These medications enhance gastrointestinal motility and improve bowel movements in CIC patients. For instance, the drug prucalopride, a selective 5-HT4 receptor agonist, has gained significant attention due to its efficacy in improving symptoms of constipation by stimulating peristalsis. Its approval in multiple regions has boosted its market presence. The growing preference for these agents is also attributed to their targeted action with fewer side effects compared to traditional laxatives, thereby improving patient outcomes and adherence to treatment. This trend is accelerating the shift towards more specialized and effective therapeutic options for CIC.
